Looking for low-cost biotech opportunities with big upside? In this video, MarketBeat’s Chris Markoch breaks down 3 speculative biotech stocks trading under $5 — each with significant growth potential and analysts’ price targets far above their current share price.
2 extracted signals · 2 resolved · 0 still active
MarketBeatIndependent analyst profile- Source published
- 14 Sept 2025, 22:25 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
AI-generated source summary
The video presents a fundamental analysis of three biotech stocks under $5. It suggests Hoth Therapeutics (HOTH), currently at $1.60, could reach $4 per share, highlighting its oncology and weight loss drug candidates. The analysis also covers Silo Pharma (SILO), priced at $0.65, noting its partnership with Hoth in obesity treatments and cryptocurrency strategy to fund operations. Anixa Biosciences (ANIX), trading at $2.93, is mentioned for its CAR-T immunotherapy program, partnered with Moffitt Cancer Center and the Cleveland Clinic, setting a price target of $9 per share. It is emphasized that while these stocks carry risk, potential gains exist for long-term investors. A free article is offered for more information, alongside text alerts for stock updates.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
2 eligible signals linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
MarketBeat
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.